Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei

ABSTRACT Azoles target the ergosterol biosynthetic enzyme lanosterol 14α-demethylase and are a widely applied class of antifungal agents because of their broad therapeutic window, wide spectrum of activity, and low toxicity. Unfortunately, azoles are generally fungistatic and resistance to fluconazole is emerging in several fungal pathogens. We recently established that the protein phosphatase calcineurin allows survival of Candida albicans during the membrane stress exerted by azoles. The calcineurin inhibitors cyclosporine A (CsA) and tacrolimus (FK506) are dramatically synergistic with azoles, resulting in potent fungicidal activity, and mutant strains lacking calcineurin are markedly hypersensitive to azoles. Here we establish that drugs targeting other enzymes in the ergosterol biosynthetic pathway (terbinafine and fenpropimorph) also exhibit dramatic synergistic antifungal activity against wild-type C. albicans when used in conjunction with CsA and FK506. Similarly, C. albicans mutant strains lacking calcineurin B are markedly hypersensitive to terbinafine and fenpropimorph. The FK506 binding protein FKBP12 is required for FK506 synergism with ergosterol biosynthesis inhibitors, and a calcineurin mutation that confers FK506 resistance abolishes drug synergism. Additionally, we provide evidence of drug synergy between the nonimmunosuppressive FK506 analog L-685,818 and fenpropimorph or terbinafine against wild-type C. albicans. These drug combinations also exert synergistic effects against two other Candida species, C. glabrata and C. krusei, which are known for intrinsic or rapidly acquired resistance to azoles. These studies demonstrate that the activity of non-azole antifungal agents that target ergosterol biosynthesis can be enhanced by inhibition of the calcineurin signaling pathway, extending their spectrum of action and providing an alternative approach by which to overcome antifungal drug resistance.

[1]  A. Guerrero,et al.  Selection ofCandida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  M. Bard,et al.  Candida albicans Sterol C-14 Reductase, Encoded by the ERG24 Gene, as a Potential Antifungal Target Site , 2002, Antimicrobial Agents and Chemotherapy.

[3]  C. Munro,et al.  Anti-fungal therapy at the HAART of viral therapy. , 2002, Trends in microbiology.

[4]  J. Maguire,et al.  Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. , 2002, The New England journal of medicine.

[5]  Joseph Heitman,et al.  Calcineurin is essential for survival during membrane stress in Candida albicans , 2002, The EMBO journal.

[6]  P. Nghiem,et al.  Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. , 2002, Journal of the American Academy of Dermatology.

[7]  J. Heitman,et al.  Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR , 2001, Antimicrobial Agents and Chemotherapy.

[8]  D. Simon,et al.  Infectious complications of solid organ transplantations. , 2001, Infectious disease clinics of North America.

[9]  Nina Singh,et al.  Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. , 2001, Emerging infectious diseases.

[10]  D. Poutsiaka Antimicrobial resistance in the chronically critically ill patient. , 2001, Clinics in chest medicine.

[11]  M. Libman,et al.  Prevalence and Antifungal Susceptibility of 442Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada , 2001, Journal of Clinical Microbiology.

[12]  D. Sanglard,et al.  Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.

[13]  R. Auten,et al.  When to Suspect Fungal Infection in Neonates: A Clinical Comparison of Candida albicans and Candida parapsilosis Fungemia With Coagulase-Negative Staphylococcal Bacteremia , 2000, Pediatrics.

[14]  D. Sanglard,et al.  Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.

[15]  R. Hay The management of superficial candidiasis. , 1999, Journal of the American Academy of Dermatology.

[16]  S. Kohno,et al.  Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. , 1998, The Journal of antimicrobial chemotherapy.

[17]  F. T. P. Group,et al.  International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program , 1998, Journal of Clinical Microbiology.

[18]  M. Bard,et al.  Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants , 1998, Antimicrobial Agents and Chemotherapy.

[19]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[20]  Ronald N. Jones,et al.  National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. , 1998, Diagnostic microbiology and infectious disease.

[21]  S. Kohno,et al.  Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains , 1998 .

[22]  J. Heitman,et al.  The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein , 1997, Antimicrobial agents and chemotherapy.

[23]  S. Kelly,et al.  Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[24]  S. Kelly,et al.  Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance , 1996, Antimicrobial agents and chemotherapy.

[25]  A. Sierra,et al.  Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. , 1996, Chemotherapy.

[26]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[27]  Anna Tempczyk,et al.  Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.

[28]  P. Caron,et al.  X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex , 1995, Cell.

[29]  M. Su,et al.  Interaction of FKBP12-FK506 with Calcineurin A at the B Subunit-binding Domain (*) , 1995, The Journal of Biological Chemistry.

[30]  R. S. Muir,et al.  Targets of immunophilin‐immunosuppressant complexes are distinct highly conserved regions of calcineurin A. , 1995, The EMBO journal.

[31]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[32]  F. McKeon,et al.  The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation , 1994, Cell.

[33]  J. Springer,et al.  FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. , 1994, The Journal of biological chemistry.

[34]  R. Handschumacher,et al.  Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. , 1993, The Journal of biological chemistry.

[35]  D. Irwin,et al.  Isogenic strain construction and gene mapping in Candida albicans. , 1993, Genetics.

[36]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[37]  J J Burbaum,et al.  Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. , 1993, The Journal of biological chemistry.

[38]  M G Rinaldi,et al.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.

[39]  A. Jandrositz,et al.  The gene encoding squalene epoxidase from Saccharomyces cerevisiae: cloning and characterization. , 1991, Gene.

[40]  F. Karst,et al.  In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property , 1990, Antimicrobial Agents and Chemotherapy.

[41]  P. Marichal,et al.  Anti-Candida drugs--the biochemical basis for their activity. , 1987, Critical reviews in microbiology.

[42]  H. Vanden Bossche Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. , 1985, Current topics in medical mycology.

[43]  F. Odds,et al.  Candida and candidosis , 1979 .

[44]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .